Cara Therapeutics, Inc. CARA
Set alert
5.32 0.00 0.00%
At close · Apr 15
5.28 Day range 5.52
52-week range unavailable
- YTD
- -71.02%
- 1 year
- -79.19%
- Open
- 4.80
- Prev close
- 5.32
- Mkt cap
- 25.09M
- Vol
- 236.84K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.28
- High
- 5.52
- Forward P/E
- -0.59
- Beta
- 0.68
- Short ratio
- 2.20
- Inst. own
- 28.16%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.29152
- 200-d avg
- 0.46241
- 1y target
- 1.01
2Y chart
Events in this range
- Aug 7, 2023Earnings: -0.58; estimate -0.56; surprise -3.57%
- Nov 13, 2023Earnings: -0.52; estimate -0.53; surprise 1.89%
- Mar 4, 2024Earnings: -0.59; estimate -0.57; surprise -3.51%
- May 13, 2024Earnings: -0.56; estimate -0.38; surprise -47.37%
- May 14, 2024Rating: Needham · Buy → Buy
- May 15, 2024Rating: HC Wainwright & Co. · Buy → Buy
- May 23, 2024Rating: Needham · Buy → Buy
- Jun 13, 2024Downgrade: Needham · Buy → Hold
- Jun 13, 2024Downgrade: HC Wainwright & Co. · Buy → Neutral
- Jun 13, 2024Downgrade: Canaccord Genuity · Buy → Hold
- Aug 14, 2024Earnings: -0.37; estimate -0.29; surprise -27.59%
- Nov 14, 2024Earnings: -0.15; estimate -0.25; surprise 40%
- Dec 31, 2024Split: 1 for 12
Signals (84)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| SMA: Bearish | Apr 3, 2025 | 1 year ago |
| SMA: Bullish | Apr 2, 2025 | 1 year ago |
| SMA: Bearish | Apr 1, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| SMA: Bullish | Mar 11, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 11, 2025 | 1 year ago |
| SMA: Bullish | Mar 5, 2025 | 1 year ago |
| SMA: Bearish | Mar 4, 2025 | 1 year ago |
| SMA: Bearish | Feb 27, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 18, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 13, 2025 | 1 year ago |
| SMA: Bullish | Feb 4, 2025 | 1 year ago |
| SMA: Bearish | Jan 31, 2025 | 1 year ago |
| SMA: Bullish | Jan 29, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 29, 2025 | 1 year ago |
| SMA: Bearish | Jan 28, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 24, 2025 | 1 year ago |
| SMA: Bullish | Jan 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 10, 2025 | 1 year ago |
| SMA: Bearish | Jan 3, 2025 | 1 year ago |
| SMA: Bullish | Dec 31, 2024 | 1 year ago |
| SMA: Bearish | Dec 26, 2024 | 1 year ago |
| SMA: Bullish | Dec 24, 2024 | 1 year ago |
| SMA: Bullish | Dec 19, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 19, 2024 | 1 year ago |
| RSI: Overbought | Dec 19, 2024 | 1 year ago |
| SMA: Bearish | Dec 10, 2024 | 1 year ago |
| SMA: Bullish | Dec 9, 2024 | 1 year ago |
| SMA: Bearish | Dec 3, 2024 | 1 year ago |
| SMA: Bullish | Nov 29, 2024 | 1 year ago |
| SMA: Bearish | Nov 27, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 18, 2024 | 1 year ago |
| RSI: Overbought | Nov 7, 2024 | 1 year ago |
| SMA: Bullish | Oct 31, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 17, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 7, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 20, 2024 | 2 years ago |
| RSI: Oversold | Sep 13, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 5, 2024 | 2 years ago |
| SMA: Bearish | Sep 3, 2024 | 2 years ago |
| SMA: Bullish | Aug 22, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 5, 2024 | 2 years ago |
| RSI: Oversold | Jun 28, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 13, 2024 | 2 years ago |
| RSI: Oversold | Jun 13, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 12, 2024 | 2 years ago |
| MACD: Sell Signal | May 24, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 30, 2024 | 2 years ago |
| SMA: Bearish | Apr 12, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 13, 2024 | 2 years ago |
| RSI: Overbought | Feb 23, 2024 | 2 years ago |
| SMA: Bullish | Feb 22, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 18, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 16, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 9, 2024 | 2 years ago |
| SMA: Bearish | Dec 18, 2023 | 2 years ago |
| MACD: Sell Signal | Dec 18, 2023 | 2 years ago |
| RSI: Oversold | Dec 18, 2023 | 2 years ago |
| SMA: Bullish | Dec 15, 2023 | 2 years ago |
| SMA: Bearish | Dec 11, 2023 | 2 years ago |
| SMA: Bullish | Dec 8, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 28, 2023 | 2 years ago |
| MACD: Sell Signal | Nov 27, 2023 | 2 years ago |
| MACD: Buy Signal | Oct 31, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 27, 2023 | 3 years ago |
| RSI: Oversold | Oct 27, 2023 | 3 years ago |
| RSI: Oversold | Oct 9, 2023 | 3 years ago |
| RSI: Oversold | Oct 4, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 27, 2023 | 3 years ago |
| RSI: Oversold | Sep 1, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 16, 2023 | 3 years ago |
| SMA: Bearish | Aug 11, 2023 | 3 years ago |
| SMA: Bullish | Aug 10, 2023 | 3 years ago |
| SMA: Bearish | Aug 7, 2023 | 3 years ago |
| SMA: Bullish | Aug 3, 2023 | 3 years ago |
| SMA: Bearish | Aug 1, 2023 | 3 years ago |
| SMA: Bullish | Jul 28, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 14, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 29, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 12, 2023 | 3 years ago |
| RSI: Oversold | May 31, 2023 | 3 years ago |
| RSI: Oversold | May 25, 2023 | 3 years ago |
Key statistics
- Market cap
- 25.09M
- Enterprise value
- 7.61M
- Trailing P/E
- 0.00
- Forward P/E
- -0.59
- PEG ratio
- 0.00
- Price / sales
- 2.28
- Price / book
- 0.44
- EPS (TTM)
- -1.75
- Beta
- 0.68
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 11.00M
- Revenue growth
- -85.70%
- Free cash flow
- -47.50M
- Total cash
- 56.62M
- Total debt
- 47.16M
- Return on equity
- -184.32%
- Shares outstanding
- 54.86M
- Short % of float
- 2.00%
- 50-day average
- 0.29152
- 200-day average
- 0.46241
Analyst view
Consensus: hold
Hold
Price target (mean) 1.01 -81.0% downside
Now 5.32
- Target (low)
- 1.00
- Target (mean)
- 1.01
- Target (high)
- 1.02
Ratings (0m) 2 0 buy · 2 hold · 0 sell
- Strong buy0
- Buy0
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
CARA Revenue — quarterly 1.46M
CARA Net income — quarterly -7.68M
CARA EPS — quarterly -1.73
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.25 | -0.15 | +0.10 | +40.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.29 | -0.37 | -0.08 | -27.59% |
| May 13, 2024 | Mar 1, 2024 | -0.38 | -0.56 | -0.18 | -47.37% |
| Mar 4, 2024 | Dec 1, 2023 | -0.57 | -0.59 | -0.02 | -3.51% |
| Nov 13, 2023 | Sep 1, 2023 | -0.53 | -0.52 | +0.01 | +1.89% |
| Aug 7, 2023 | Jun 1, 2023 | -0.56 | -0.58 | -0.02 | -3.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 13, 2024 | Canaccord Genuity | down | Buy | Hold |
| Jun 13, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 13, 2024 | Needham | down | Buy | Hold |
| May 23, 2024 | Needham | reit | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2024 | Needham | reit | Buy | Buy |
About Cara Therapeutics, Inc.
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- caratherapeutics.com
News
- Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
- Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics
- Cannabis Stock Gainers And Losers From April 10, 2025
- Bullish Sentiment Across The Cannabis Space - Check Full Movers For April 1, 2025
- CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA
- CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA
- Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split
- GRAMMY-WINNING ARTIST ALESSIA CARA PARTNERS WITH LENOVO AND INTEL FOR THE "MADE BY" CAMPAIGN, FEATURING A BEHIND-THE-SCENES MINISERIES AND EXCLUSIVE LIVE EXPERIENCE
- $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cara Therapeutics, Inc. - CARA
- Shareholder Alert: Ademi LLP Investigates Whether Cara Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Your note
Sign in to keep a note on CARA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOUDREAU HELEN M. | Director | Stock Award(Grant) | Jun 3, 2024 | 150,647 |
| GONCALVES JOANA | Officer | Sale | Apr 4, 2024 | 53,365 |
| IVES JEFFREY L | Director | Stock Award(Grant) | Jun 3, 2024 | 198,485 |
| MAYNARD RYAN D | Chief Financial Officer | Stock Award(Grant) | Jan 31, 2024 | 13,500 |
| MENZAGHI FREDERIQUE | Officer | Stock Award(Grant) | Jan 31, 2024 | 167,247 |
| POSNER CHRISTOPHER | Chief Executive Officer | Sale | Nov 3, 2024 | 168,768 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 4.10% | 2,248,911 | 1.03M | Sep 29, 2024 |
| Chescapmanager LLC | 3.10% | 1,702,110 | 778.54K | Sep 29, 2024 |
| Farallon Capital Management LLC | 2.84% | 1,556,251 | 711.83K | Sep 29, 2024 |
| Disciplined Growth Investors, Inc. | 2.03% | 1,113,043 | 509.11K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 2.02% | 1,108,931 | 507.23K | Sep 29, 2024 |
| Two Sigma Advisers, LP | 1.58% | 866,300 | 396.25K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.47% | 1,354,313 | 619.46K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.18% | 645,753 | 295.37K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.48% | 261,602 | 119.66K | Oct 30, 2024 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.41% | 224,141 | 102.52K | Aug 30, 2024 |
| Vanguard Health Care Index Fund | 0.30% | 165,236 | 75.58K | Aug 30, 2024 |
| Fidelity Enhanced Small Cap ETF | 0.28% | 155,032 | 70.91K | Oct 30, 2024 |